In short
There is currently 1 ongoing clinical trial for acoustic neuroma, also known as vestibular schwannoma. This trial is investigating whether nimodipine, a calcium channel blocker, can help preserve hearing function after surgery for this non-cancerous growth on the nerve connecting the ear to the brain.
Clinical trial locations
- Germany
Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery
This trial is investigating whether nimodipine can help protect hearing ability in patients having surgery to remove a vestibular schwannoma. The medication is given as an infusion directly into the bloodstream during the surgical period.
Who can join this trial?
Adults aged 18 years or older with vestibular schwannomas who need surgery can participate. To be eligible, participants must have had a hearing test within three months before surgery, showing hearing within a certain range according to the Gardner-Robertson scale. They also need to have had an MRI scan within six months before surgery. Participants must be able to understand the study and provide written consent to join. Those of childbearing potential must use reliable contraception methods.
Who cannot join this trial?
Patients outside the age range of 18 to 64 years cannot participate. Those unable to undergo surgery or who have medical conditions that make nimodipine unsafe for them are excluded. Pregnant or breastfeeding women cannot join the trial. Patients who cannot understand the study enough to give informed consent are not eligible, nor are those already participating in another clinical trial at the same time.
What is the trial studying?
The main focus is to evaluate how effective and safe nimodipine is in maintaining hearing after surgery compared to standard care. The trial will monitor participants' hearing function before surgery, after surgery before discharge, and again three to six months later. Researchers will assess any changes in hearing levels and participants' overall quality of life. The study will also carefully track any side effects or safety concerns, particularly changes in blood pressure. The trial is expected to continue until March 2026.
About the medication
Nimodipine is a calcium channel blocker that works by relaxing and widening blood vessels, which improves blood flow and may reduce the risk of nerve damage during surgery. While it is already known for preventing brain damage caused by reduced blood flow, this trial is exploring whether it can protect hearing function during ear-related surgery.
Summary
Currently, there is one active clinical trial for acoustic neuroma, taking place in Germany. This trial represents an important investigation into hearing preservation during surgery for this condition. The study focuses specifically on nimodipine, a medication that may help protect the delicate hearing nerve during surgical removal of the tumor. Patients interested in participating should meet the specific age and health criteria outlined in the trial and be prepared for follow-up assessments over several months after surgery.
